Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Active, not recruiting · NCT06144944 · Registry updated 2026-08-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-18 | NCT06144944 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 132 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 285 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Guangzhou | China | 21 |